Work

Battling the two-headed dragon of prostate cancer targeted therapy

Year: 2020

Type: article

Abstract: Neoadjuvant intense androgen deprivation therapy for high-risk localized prostate cancer is an emerging but unproven treatment paradigm that is hoped to delay or prevent disease recurrence. We found that a patient enrolled in a clinical trial harbored two completely independent prostate cancers that responded differently to this therapy.

Source: Molecular & Cellular Oncology

DOI: 10.1080/23723556.2020.1745037

Authors: Scott Wilkinson, Adam G. Sowalsky

Institution: National Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $1,590